VivoSeq
Respiratory

Exacerbation of COPD

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Exacerbation of COPD is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Not yet recruiting1 · 20%
Unknown status1 · 20%

Clinical Trials

Trial Activity

Acute Exacerbation of COPD and Nebulized Magnesium Sulphate
Completed·KKing Edward Medical University·N/A·NCT05699720·160 enrolled
Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD
Completed·FFadoi Foundation, Italy·Phase 4·NCT01710488·258 enrolled
Effects of Chinese Medicine on Patients With Severe Acute Exacerbation of COPD
Not yet recruiting·HHenan University of Traditional Chinese Medicine·N/A·NCT06455670·468 enrolled
Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance
Completed·—·Phase 2·NCT02674880·41 enrolled
N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD
Unknown status·QQueen Mary Hospital, Hong Kong·Phase 3·NCT05706402·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)